Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: recombinant protein therapeutics - Pharming/Transgenic Rabbit Models

Drug Profile

Research programme: recombinant protein therapeutics - Pharming/Transgenic Rabbit Models

Alternative Names: Enzyme replacement therapies - Pharming/Transgenic rabbit models; POMPE; Protein replacement therapies - Pharming/Transgenic Rabbit Models; recombinant human-alpha-galactosidase; recombinant human-alpha-glucosidase; rh-alpha-galactosidase; rh-alpha-glucosidase

Latest Information Update: 17 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Transgenic Rabbit Models
  • Developer Pharming Group NV
  • Class Alpha-glucosidases; Enzymes; Galactosidases; Recombinant proteins
  • Mechanism of Action Alpha glucosidase replacements; Alpha-galactosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Fabry's disease; Glycogen storage disease type II

Most Recent Events

  • 11 May 2023 Discontinued - Preclinical for Glycogen storage disease type II in Netherlands (Parenteral)
  • 11 May 2023 Discontinued for Fabry's disease in Netherlands (Parenteral) (Pharming Group NV pipeline, May 2023)
  • 28 Oct 2022 No recent reports of development identified for research development in Fabry's-disease in Netherlands (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top